TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells

  • Authors:
    • Biao Zheng
    • Kenoki Ohuchida
    • Lin Cui
    • Ming Zhao
    • Koji Shindo
    • Kenji Fujiwara
    • Tatsuya Manabe
    • Nobuhiro Torata
    • Taiki Moriyama
    • Yoshihiro Miyasaka
    • Takao Ohtsuka
    • Shunichi Takahata
    • Kazuhiro Mizumoto
    • Yoshinao Oda
    • Masao Tanaka
  • View Affiliations

  • Published online on: May 28, 2015     https://doi.org/10.3892/ijo.2015.3022
  • Pages: 490-498
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The cell surface protein Transmembrane 4 L6 family member 1 (TM4SF1) has been detected in various tumors, and its expression on tumor cells is implicated in cancer cell metastasis and patient prognosis. The role of TM4SF1 in malignant tumors remains poorly understood, particularly in pancreatic cancer. We performed immunohistochemical staining to analyze the expression of TM4SF1 in resected pancreatic tissues and investigated the correlation between TM4SF1 expression and prognosis. The function of TM4SF1 in the invasion and migration of pancreatic cancer cells was analyzed in vitro using an RNA interference technique. In pancreatic cancer tissues, TM4SF1 expression was detected in cancer cells, and patients with high tumor levels of TM4SF1 showed longer survival times than those with low TM4SF1 levels (P=0.0332). In vitro, reduced TM4SF1 expression enhanced the migration (P<0.05) and invasion (P<0.05) of pancreatic cancer cells partially via decreased E-cadherin expression. TM4SF1 protein levels were also reduced after TGF-β1-induced epithelial-mesenchymal transition (EMT).TM4SF1 expression is associated with better prognosis in pancreatic cancer. Loss of TM4SF1 contributes to the invasion and migration of pancreatic cancer cells.

Introduction

Pancreatic cancer is one of the most deadly malignancies. In contrast to the stable or declining trends for most other cancer types, incidence rates are increasing for cancers of the pancreas (1). Despite the use of multimodality treatment, the overall 5-year survival rate for pancreatic cancer is only six percent because of its high recurrence rate (1). Invasion and metastasis are the major causes of the poor prognosis of pancreatic cancer (2). The coordination of intercellular adhesion, cell-matrix interaction, matrix degradation, and cell migration is essential for cancer cell invasion and metastasis, and a diverse variety of transmembrane proteins regulate these cellular events (35). Notably, proteins of the tetraspanin superfamily, such as Tspan8 (6), CD82 (7), CD9 (8), and CD151 (9) are important for the regulation of tumor cell motility and the interaction between tumor cells and their microenvironment. Therefore, tetraspanins may represent promising diagnostic or prognostic markers and therapeutic targets for tumor progression (10,11).

TM4SF1 is a member of the tetraspanin superfamily (12). Tetraspanins are characterized by four transmembrane domains delimiting two extracytoplasmic regions of unequal size (13). Elevated expression of TM4SF1 has been reported in several tumor types, and is implicated in cancer cell migration and patient outcome, but it adopts different roles that are dependent upon tumor type (1417). In addition, TM4SF1 is important for endothelial cell migration and tumor angiogenesis (18,19), although the underlying mechanism of its function is not clear, especially in pancreatic cancer.

In the present study, we investigated the role of TM4SF1 in pancreatic ductal adenocarcinoma (PDAC). TM4SF1 expression in PDAC tissues was evaluated by immunohistochemistry, and the correlation between clinicopathological characteristics and TM4SF1 expression was assessed to determine its prognostic significance in PDAC. To determine the biomolecular functions of TM4SF1 in pancreatic cancer cells, we investigated changes in cell migration and invasion in vitro using a siRNA knockdown approach.

Materials and methods

Cell lines

The following six pancreatic cancer cell lines were used: KP-2, SUIT-2 (Dr H. Iguchi, National Shikoku Cancer Center, Matsuyama, Japan), MIA PaCa-2 (Japanese Cancer Resource Bank, Tokyo, Japan), Capan-1, Capan-2 and Hs766T (American Type Culture Collection, Manassas, VI, USA). The human immortalized pancreatic ductal epithelial cell line (HPDE6-E6E7 clone 6) was kindly provided by Dr Ming-Sound Tsao (University of Toronto, Toronto, Canada). All cells were maintained as previously described (20).

Pancreatic tissues

We analyzed TM4SF1 expression in 74 tissue samples obtained from patients who underwent pancreatic resection for pancreatic cancer at our institution between January 2000 and August 2009. We also obtained normal pancreatic tissue samples from intact pancreas resected for bile duct cancer as control tissues. Survival was measured from the time of pancreatic resection, with death as the end-point. Overall survival and disease-free survival analyses were performed in February 2012. The median observation time for overall survival and disease-free survival was 19 months (range 2–137 months) and 11 months (range 1–137 months), respectively. Forty-nine patients died during the follow-up. All surviving patients were censored. Histological diagnosis of specimens was in accordance with the criteria of the updated World Health Organization classification (21). Tumor stage was assessed according to the UICC classification, 7th edition (22). The clinicopathological characteristics of all patients are summarized in Table I. The study was approved by the Ethics Committee of Kyushu University and conducted according to the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government and the Helsinki Declaration.

Table I

Clinicopathological characteristics of patients with PDAC (N=74).

Table I

Clinicopathological characteristics of patients with PDAC (N=74).

Median age66.55 (range 36–86 years)
Gender (male/female)46 (62.2%)/28 (37.8%)
pT category
 T12 (2.7%)
 T22 (2.7%)
 T368 (91.9%)
 T42 (2.7%)
pN category
 pN016 (21.6%)
 pN158 (78.4%)
UICC stage
 I3 (4.1%)
 II68 (91.8%)
 III2 (2.7%)
 IV1 (1.4%)
Residual tumor category
 R052 (70.3%)
 R122 (29.7%)
Histologic grade
 Grade 113 (17.6%)
 Grade 235 (47.3%)
 Grade 326 (35.1%)
Vascular invasion
 Negative20 (27.3%)
 Positive54 (72.7%)
Perineural invasion
 Negative6 (8.2%)
 Positive68 (91.8%)
Lymphatic invasion
 Negative17 (23%)
 Positive57 (77%)
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

One-step real-time qRT-PCR using gene-specific primers was performed as described previously (23). Primer sequences were as follows: TM4SF1 forward 5′-ATTGGAAT TGCAGGATCTGG-3′ and reverse 5′-GCCGAGGGAATCAA GACATA-3′; 18S rRNA forward 5′-GTAACCCGTTGAACC CCATT-3′ and reverse 5′-CCATCCAATCGGTAGTAGCG-3′. BLAST searches were performed to ensure the specificity of all primers. Primers were purchased from Sigma Genosys (Tokyo, Japan).

Immunohistochemical procedures and evaluation

Immunohistochemistry was performed using a Histofine SAB-PO kit (Nichirei, Tokyo, Japan) (24). Sections were incubated with anti-TM4SF1 antibody (HPA002823; Sigma-Aldrich, Tokyo, Japan) overnight at 4°C. Carcinoma cells were identified according to morphology and counted in at least 20 fields per section at ×200 magnification. The distribution of TM4SF1 staining was evaluated as the percentage of stained cells, and was scored as follows: 0, no staining or <10%; 1, 11–25%; 2, 26–50%; 3, 51–75%; or 4, 76–100%. Cells were also scored for staining intensity, which was scored as 0, no staining; 1, weak; 2, moderate; or 3, strong. The multiplication product (from 0–12) from these two scores was used to assign patients into one of two groups according to TM4SF1 expression, where a score of 0–4 represented low expression and a score of 6–12 represented high expression. All slides were evaluated independently by two investigators who were unaware of the clinical features of each case.

Silencing of TM4SF1 using small interfering RNAs (siRNAs)

Gene silencing was carried out using siRNA (Qiagen, MA, USA) directed against human TM4SF1. Sequences were as follows: siRNA-1 (sense, 5′-ggaccacuaugucuugauutt-3′; antisense, 5′-aaucaagacauaguggucctt-3′); siRNA-2 (sense, 5′-cgaug acugggcaagaagatt-3′; antisense, 5′-ucuucuugcccagucaucgta-3′). Qiagen all-star siRNA was used as a negative control. Transfections were performed as described previously (25). All cells were used in subsequent experiments 48 h after transfection.

Matrigel invasion and migration assays

Migration and invasion of cultured cancer cells were assessed by counting the number of cells migrating or invading through uncoated or Matrigel-coated transwell chambers (BD Biosciences, Franklin Lakes, NJ, USA) as described previously (20,26). Cells were maintained in 10% FBS/DMEM during these assays. Cells were transfected with siRNAs 48 h prior to experimentation. Migration was determined after a 24-h period, and invasiveness was determined after a 48-h period.

TGF-β1 treatment

SUIT-2 and Capan-2 cells were cultured in 6-well plates (1×105 cells/well) in 1% FBS/DMEM with or without 10 ng/ml recombinant human TGF-β1 (R&D, Oxon, UK) for 24 and 48 h (27). At each time-point, total RNA was extracted to evaluate TM4SF1 mRNA expression by qRT-PCR. To evaluate TM4SF1 protein levels, cells were seeded in 90-mm dishes at a density of 2×105 cells/dish and cultured in 1% FBS/DMEM with or without 10 ng/ml TGF-β1 prior to cell lysis.

Western blot analysis

Western blotting was performed as described previously (28). Antibodies used in this study were as follows: anti-TM4SF1 (sc-103267; Santa Cruz, CA, USA), anti-E-cadherin (no. 3195), anti-vimentin (no. 5741), anti-N-cadherin (no. 4061), anti-claudin-1 (no. 4933) (Cell Signaling Technology, Danvers, MA, USA) and anti-β actin (ab8227; Abcam, Cambridge, MA, USA).

Statistical analysis

A χ2 test was used to analyze the correlation between TM4SF1 expression and clinicopathological characteristics. Survival analysis was performed using Kaplan-Meier analysis and curves were compared using the log-rank test. For in vitro experiments, values are expressed as means ± standard deviation. Comparison between two groups was performed using the Student’s t-test. Statistical significance was defined as P<0.05. All statistical analyses were performed using JMP 9.0.2 software (SAS Institute, NC, USA).

Results

Pancreatic cancer cells express TM4SF1

We first sought to determine the level of TM4SF1 expression in PDAC and normal pancreatic tissues. In normal pancreatic tissues, weak-to-no staining was detected in pancreatic ductal epithelial cells and TM4SF1 expression was not observed in acinar cells or stroma. Blood vessels consistently stained positive for TM4SF1, and were used as a positive control (Fig. 1A-a and -c). In tumor tissues, strong luminal membrane surface staining and a weak-to-moderate cytoplasmic staining was detected in cancer cells (Fig. 1A-b). In addition to tumor tissue samples where moderate staining was observed, there were also tumor tissue samples where little-to-no staining was observed (Fig. 1A-c).

Prognostic significance of TM4SF1 expression

Survival analysis was performed for patients with PDAC. The high TM4SF1 expression group showed better survival (P=0.0332; Fig. 1B) than the low expression group, and there was an obvious difference in the disease-free time between the groups (P=0.0409; Fig. 1B). Median survival was 30 months for the high expression group and 17 months for the low expression group (Table II). Next, we performed multivariate analysis based on the Cox proportional hazard model on all parameters that were found to be significant in the univariate analyses. Overall survival was significantly dependent on residual tumor (R1) status (relative risk = 2.732, P=0.0017), vascular invasion (relative risk = 2.461, P=0.0101) and low TM4SF1 expression (relative risk = 1.987, P=0.0196) (Table III).

Table II

Univariate survival analysis of conventional prognostic factors and TM4SF1 expression in PDAC patient resections (N=74).

Table II

Univariate survival analysis of conventional prognostic factors and TM4SF1 expression in PDAC patient resections (N=74).

CharacteristicsNo. of casesMedian survival time (months)5-year survival rateP-value
TM4SF1 expression0.0332
 High353040.8
 Low391713.2
Age (years)0.3099
 <65272338.0
 ≥65472317.7
UICC stage0.0774
 I/IIA156044.1
 IIB/III/IV591918.6
Histological grade0.4285
 Grade 1/grade 2482330.8
 Grade 3261914.2
Residual tumor0.0001
 R0523036.8
 R122112.8
Vascular invasion0.0079
 Negative206053.1
 Positive541714.0
Perineural invasion0.1458
 Negative69060.3
 Positive681923.8
Lymphatic invasion0.0667
 Negative176046.5
 Positive571921.0

Table III

Multivariate analysis of conventional prognostic factors and TM4SF1 expression in PDAC patients (N=74).

Table III

Multivariate analysis of conventional prognostic factors and TM4SF1 expression in PDAC patients (N=74).

CharacteristicsRelative risk95% confidence intervalP-value
Low TM4SF1 expression1.9871.116–3.6320.0196
R factor2.7321.479–4.9490.0017
Vascular invasion2.4611.226–5.5030.0101

The relationship between TM4SF1 expression and clinicopathological factors of PDAC is shown in Table IV. There was no statistically significant correlation between TM4SF1 expression and clinicopathological factors possibly due to the relatively small size of the patient cohort, although it appears that the patients with low expression have a higher tumor grade and a more advanced clinical stage. Because there was an obvious difference in the disease-free time, we analyzed the site of first recurrence (Fig. 1C) and found that the locoregional recurrence rate in the low TM4SF1 expression group (28.21%) was higher than in the high expression group (5.71%; P=0.0079) although the total recurrence rates for the two patients groups were similar (Table V). The data suggest that tumors with low TM4SF1 expression undergo local spread more frequently than those with high expression, and this may contribute to the observed survival differences.

Table IV

Relationship between TM4SF1 expression and various clinicopathological factors in patients with PDAC (N=74).

Table IV

Relationship between TM4SF1 expression and various clinicopathological factors in patients with PDAC (N=74).

CharacteristicsHigh expression group
n=35 (47.3%)
Low expression group
n=39 (52.7%)
P-value
Age (years)0.9115
 <6513 (37.14)14 (35.90)
 ≥6522 (62.86)25 (64.10)
pT category0.9114
 pT1/pT22 (5.71)2 (5.13)
 pT3/pT433 (94.29)37 (94.87)
pN Category0.4179
 pNo9 (25.71)7 (17.95)
 pN126 (74.29)32 (82.05)
UICC stage0.6002
 I/IIA8 (22.86)7 (17.95)
 IIB/III/IV27 (77.14)32 (82.05)
Histological grade0.5263
 Grade 1/grade 224 (68.57)24 (61.54)
 Grade 311 (31.43)15 (38.46)
Residual tumor category0.8363
 R025 (71.43)27 (69.23)
 R110 (28.57)12 (30.77)
Lymphatic invasion0.9821
 Negative8 (22.86)9 (23.08)
 Positive27 (77.14)30 (76.92)
Vascular invasion0.8095
 Negative9 (25.71)11 (28.21)
 Positive26 (74.29)28 (71.79)
Perineural invasion0.3189
 Negative4 (11.43)2 (5.13)
 Positive31 (88.57)37 (94.87)

Table V

Relationship between TM4SF1 expression and patterns of recurrence in patients with PDAC (N=74).

Table V

Relationship between TM4SF1 expression and patterns of recurrence in patients with PDAC (N=74).

CharacteristicsHigh expression group
n=35 (47.3%)
Low expression group
n=39 (52.7%)
P-value
Total recurrence0.1823
 Negative12 (34.29)8 (20.51)
 Positive23 (65.71)31 (79.49)
Local recurrence0.0079
 Negative33 (94.29)28 (71.79)
 Positive2 (5.71)11 (28.21)
Hematogenous dissemination0.8363
 Negative21 (60.00)29 (74.36)
 Positive14 (40.00)10 (25.64)
Peritoneal recurrence0.3866
 Negative29 (82.86)35 (89.74)
 Positive6 (17.14)4 (10.26)
Distant lymphatic metastasis0.0647
 Negative34 (97.14)34 (87.18)
 Positive1 (2.86)5 (12.82)
Inhibition of TM4SF1 expression promotes migration and invasion of pancreatic cancer cells

We also determined the level of TM4SF1 expression in a variety of pancreatic cancer cell lines, and the level of TM4SF1 mRNA expression was found to be higher in pancreatic cancer cell lines than in normal (HPDE) epithelial cells (Fig. 2A). Because local tumor invasion is more likely in patients with low TM4SF1 tumor expression, and because TM4SF1 has been reported to be involved in the migration of cancer cells (14,15), we next performed migration and invasion assays following knockdown of TM4SF1 in pancreatic cancer cells. Decreased TM4SF1 protein expression was confirmed by western blotting following transfection of cells with TM4SF1-specific siRNA (Fig. 2B). The invasion and migration of two cell lines studied, SUIT-2 and Capan-2, were enhanced following siRNA-mediated knockdown of TM4SF1 (Fig. 2C). These suggest that TM4SF1 has an inhibitory role in the invasion and migration of pancreatic cancer cells.

E-cadherin expression is reduced in pancreatic cancer cells following knockdown of TM4SF1

Because the process of cancer invasion requires epithelial tumor cells to undergo epithelial to mesenchymal transition (EMT) either transiently or stably (29), we examined the correlation between the expression of TM4SF1 and EMT markers in vitro. We found that E-cadherin expression was reduced after knockdown of TM4SF1, but there were no changes in the expression of other makers including vimentin, N-cadherin and claudin-1 (Fig. 3A). Changes in cell morphology, however, were not observed after knockdown of TM4SF1 (data not shown).

TGF-β1 negatively regulates TM4SF1 expression

TGF-β1 is a major inducer of EMT in a number of cellular contexts (30), and plays a pivotal role in driving EMT in the pathogenesis of pancreatic cancer (27,31). To investigate whether TGF-β1 influences TM4SF1 expression, we performed additional in vitro analyses on pancreatic cancer cells treated with TGF-β1. Western blot analysis revealed that TGF-β1 treatment significantly downregulated E-cadherin expression and upregulated vimentin expression in both these cell lines. TM4SF1 protein levels were also reduced following treatment with TGF-β1 for 48 h (Fig. 3B).

Discussion

TM4SF1 is a tumor-associated antigen that is detected widely in human carcinomas (32), and it represents a promising target for antibody-mediated immunotherapy (33). However, the exact role of TM4SF1 in cancer remains controversial. TM4SF1 is reported to be a prognostic marker in a number of malignant tumors. In lung (14) and colorectal cancer (34) patients, increased expression of TM4SF1 was shown to be significantly associated with early postoperative relapse and shorter survival. In contrast, our study revealed that decreased expression of TM4SF1 was significantly associated with shorter survival and early local spread in PDAC patients, suggesting that TM4SF1 plays an inhibitory role in pancreatic cancer relapse and tumor progression. These results are consistent with those of a previous study of TM4SF1 in mesothelioma patients (16). Furthermore, serial analysis of gene expression in breast cancer tissues revealed a negative correlation between TM4SF1 expression and progression of breast carcinomas (17). These data suggest that TM4SF1 may be a novel predictive marker of good prognosis in several tumors including PDAC, although the clinical significance of TM4SF1 expression varies depending on tumor type.

With respect to the cellular functions of TM4SF1, it has previously been reported that high expression of TM4SF1 increases the invasiveness of lung carcinoma cells (14) and the migration of prostate cancer cells (15). Our study demonstrates a contrasting function for TM4SF1 in pancreatic cancer cells as cancer cell motility was enhanced following inhibition of TM4SF1 expression, a finding which may account for the differences in local recurrence rate and prognosis among PDAC patients. Furthermore, we found that knockdown of TM4SF1 reduced E-cadherin expression in pancreatic cancer cells (although other EMT markers examined were unaffected) and that treatment with TGF-β1 downregulated TM4SF1 in these cells. E-cadherin is closely implicated in the motility of cancer cells (35), and loss of E-cadherin expression is associated with poor clinical outcome in several cancer types (36,37) including pancreatic cancer (38). Our findings therefore suggest a role for TM4SF1 in TGF-β1-induced EMT, and that TM4SF1 may alter the migration of pancreatic cancer cells partially via regulating E-cadherin expression. Targeting TM4SF1 expression may therefore potentially lead to the development of promising therapies for several types of tumor, including PDAC.

Previous reports indicate that tetraspanins, through protein-protein and protein-lipid interactions, recruit various transmembrane and cytoplasmic proteins to form tetraspanin-enriched microdomains (TERM), functional complexes involved in cell migration (39). Tetraspanins interact with a variety of transmembrane proteins, participate in various TERM formations, and can perform different functions in a variety of cell types. For example, CD151, one of the tetraspanin members, regulates cell migration in a cell type-specific manner (40). The CD151-α6β4 complex is a major component of hemidesmosomes in skin keratinocytes, structures that oppose cell migration by stabilizing cell attachment to the extracellular matrix (41). However, in human cervical carcinoma cells, CD151 promotes tumor cell migration but does not appear to affect cell adhesion to matrix proteins (42). TM4SF1 is also associated with TERM, and influences cell motility via regulating the surface presentation and endocytosis of a number of components of these complexes (43). Therefore, we speculate that in diverse tissues or cell types, TM4SF1 may interact with different transmembrane proteins (such as E-cadherin) and influence cell migration by modulating the endocytosis and recycling of proteins associated with motility.

In conclusion, our results suggest that TM4SF1 plays an inhibitory role in the migration and invasion of pancreatic cancer cells. Further investigation is now needed to elucidate the mechanisms of interaction between TM4SF1 and either E-cadherin or TGF-β1 in the migration and invasion of pancreatic cancer cells. Furthermore, decreased expression of TM4SF1 is significantly associated with shorter survival in PDAC patients, suggesting that TM4SF1 is a promising prognostic biomarker in PDAC.

Acknowledgements

This study was supported by Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant nos. 26293305 and 25293285). We are grateful to Emiko Manabe and Miyuki Omori (Department of Surgery and Oncology, Kyushu University) for skillful technical assistance, and thankful for scholarships to Biao Zheng by China Scholarship Council (http://www.csc.edu.cn/).

References

1 

Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI

2 

DiMagno EP, Reber HA and Tempero MA; American Gastroenterological Association. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 117:1464–1484. 1999. View Article : Google Scholar : PubMed/NCBI

3 

Ellenrieder V, Adler G and Gress TM: Invasion and metastasis in pancreatic cancer. Ann Oncol. 10(Suppl 4): S46–S50. 1999. View Article : Google Scholar

4 

Boucheix C, Duc GH, Jasmin C and Rubinstein E: Tetraspanins and malignancy. Expert Rev Mol Med. 2001:1–17. 2001.

5 

Zöller M: Tetraspanins: Push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 9:40–55. 2009. View Article : Google Scholar

6 

Kanetaka K, Sakamoto M, Yamamoto Y, Takamura M, Kanematsu T and Hirohashi S: Possible involvement of tetraspanin CO-029 in hematogenous intrahepatic metastasis of liver cancer cells. J Gastroenterol Hepatol. 18:1309–1314. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Ruseva Z, Geiger PX, Hutzler P, Kotzsch M, Luber B, Schmitt M, Gross E and Reuning U: Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation. Exp Cell Res. 315:1759–1771. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Longo N, Yáñez-Mó M, Mittelbrunn M, de la Rosa G, Muñoz ML, Sánchez-Madrid F and Sánchez-Mateos P: Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood. 98:3717–3726. 2001. View Article : Google Scholar : PubMed/NCBI

9 

Novitskaya V, Romanska H, Dawoud M, Jones JL and Berditchevski F: Tetraspanin CD151 regulates growth of mammary epithelial cells in three-dimensional extracellular matrix: Implication for mammary ductal carcinoma in situ. Cancer Res. 70:4698–4708. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M and Miyake M: Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res. 56:1751–1755. 1996.PubMed/NCBI

11 

Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, Nishida M, Katsube F, Watabe K, Kiso S, Tsutsui S, et al: A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol. 44:889–896. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Marken JS, Schieven GL, Hellström I, Hellström KE and Aruffo A: Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci USA. 89:3503–3507. 1992. View Article : Google Scholar : PubMed/NCBI

13 

Maecker HT, Todd SC and Levy S: The tetraspanin superfamily: molecular facilitators. FASEB J. 11:428–442. 1997.PubMed/NCBI

14 

Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW and Roffler SR: Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res. 9:2807–2816. 2003.PubMed/NCBI

15 

Allioli N, Vincent S, Vlaeminck-Guillem V, Decaussin-Petrucci M, Ragage F, Ruffion A and Samarut J: TM4SF1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration. Prostate. 71:1239–1250. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, Jaklitsch MT, Sugarbaker DJ and Bueno R: Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 95:598–605. 2003. View Article : Google Scholar : PubMed/NCBI

17 

Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K and Aldaz CM: Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res. 6:R499–R513. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Zukauskas A, Merley A, Li D, Ang LH, Sciuto TE, Salman S, Dvorak AM, Dvorak HF and Jaminet SC: TM4SF1: A tetraspanin-like protein necessary for nanopodia formation and endothelial cell migration. Angiogenesis. 14:345–354. 2011. View Article : Google Scholar : PubMed/NCBI

19 

Shih SC, Zukauskas A, Li D, Liu G, Ang LH, Nagy JA, Brown LF and Dvorak HF: The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res. 69:3272–3277. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, Matsumoto K, Nakamura T and Tanaka M: Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 64:3215–3222. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Hruban RH, Klöppel G, Boffetta P, et al: Ductal adenocarcinoma of the pancreas. WHO Classification of Tumours of the Digestive System. World Health Organization; pp. 281–291. 2010

22 

Edge SB, Byrd DR, Compton CC, et al: Exocrine and Endocrine Pancreas, AJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: pp. 241–248. 2010

23 

Cui L, Ohuchida K, Mizumoto K, Moriyama T, Onimaru M, Nakata K, Nabae T, Ueki T, Sato N, Tominaga Y, et al: Prospectively isolated cancer-associated CD10 (+) fibroblasts have stronger interactions with CD133 (+) colon cancer cells than with CD133 (−) cancer cells. PLoS One. 5:e121212010. View Article : Google Scholar

24 

Ikenaga N, Ohuchida K, Mizumoto K, Cui L, Kayashima T, Morimatsu K, Moriyama T, Nakata K, Fujita H and Tanaka M: CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology. 139:1041–1051. 51 e1–8. 2010. View Article : Google Scholar

25 

Moriyama T, Ohuchida K, Mizumoto K, Cui L, Ikenaga N, Sato N and Tanaka M: Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer. 116:3357–3368. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Iwamoto Y, Tanaka K, Okuyama K, Sugioka Y and Taniguchi S: In vitro assay of the invasive potential of malignant bone and soft tissue tumours through basement membranes. Int Orthop. 18:240–247. 1994. View Article : Google Scholar : PubMed/NCBI

27 

Ikenaga N, Ohuchida K, Mizumoto K, Akagawa S, Fujiwara K, Eguchi D, Kozono S, Ohtsuka T, Takahata S and Tanaka M: Pancreatic cancer cells enhance the ability of collagen internalization during epithelial-mesenchymal transition. PLoS One. 7:e404342012. View Article : Google Scholar : PubMed/NCBI

28 

Kozono S, Ohuchida K, Eguchi D, Ikenaga N, Fujiwara K, Cui L, Mizumoto K and Tanaka M: Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 73:2345–2356. 2013. View Article : Google Scholar : PubMed/NCBI

29 

De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Moustakas A and Heldin CH: Induction of epithelial-mesenchymal transition by transforming growth factor β. Semin Cancer Biol. 22:446–454. 2012. View Article : Google Scholar : PubMed/NCBI

31 

Lou C, Zhang F, Yang M, Zhao J, Zeng W, Fang X, Zhang Y, Zhang C and Liang W: Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One. 7:e509562012. View Article : Google Scholar

32 

Svensson HP, Frank IS, Berry KK and Senter PD: Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma. J Med Chem. 41:1507–1512. 1998. View Article : Google Scholar : PubMed/NCBI

33 

Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW, et al: A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo. J Immunother. 35:235–244. 2012. View Article : Google Scholar : PubMed/NCBI

34 

Schiedeck TH, Wellm C, Roblick UJ, Broll R and Bruch HP: Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis Colon Rectum. 46:818–825. 2003. View Article : Google Scholar : PubMed/NCBI

35 

Kang Y and Massagué J: Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM and Schalken JA: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 53:3241–3245. 1993.PubMed/NCBI

37 

Endo K, Ueda T, Ueyama J, Ohta T and Terada T: Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: Relationships with tumor grade, clinicopathologic parameters, and patients’ survival. Hum Pathol. 31:558–565. 2000. View Article : Google Scholar : PubMed/NCBI

38 

Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K, Kosuge T, Sekihara H and Hirohashi S: Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: Relationship to e-cadherin expression. J Clin Oncol. 21:659–667. 2003. View Article : Google Scholar : PubMed/NCBI

39 

Hemler ME: Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 19:397–422. 2003. View Article : Google Scholar : PubMed/NCBI

40 

Berditchevski F: Complexes of tetraspanins with integrins: More than meets the eye. J Cell Sci. 114:4143–4151. 2001.PubMed/NCBI

41 

Sterk LM, Geuijen CA, Oomen LC, Calafat J, Janssen H and Sonnenberg A: The tetraspan molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin alpha6beta4 and may regulate the spatial organization of hemidesmosomes. J Cell Biol. 149:969–982. 2000. View Article : Google Scholar : PubMed/NCBI

42 

Testa JE, Brooks PC, Lin JM and Quigley JP: Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res. 59:3812–3820. 1999.PubMed/NCBI

43 

Lekishvili T, Fromm E, Mujoomdar M and Berditchevski F: The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: Implication for tumour cell motility. J Cell Sci. 121:685–694. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August-2015
Volume 47 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zheng B, Ohuchida K, Cui L, Zhao M, Shindo K, Fujiwara K, Manabe T, Torata N, Moriyama T, Miyasaka Y, Miyasaka Y, et al: TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells. Int J Oncol 47: 490-498, 2015
APA
Zheng, B., Ohuchida, K., Cui, L., Zhao, M., Shindo, K., Fujiwara, K. ... Tanaka, M. (2015). TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells. International Journal of Oncology, 47, 490-498. https://doi.org/10.3892/ijo.2015.3022
MLA
Zheng, B., Ohuchida, K., Cui, L., Zhao, M., Shindo, K., Fujiwara, K., Manabe, T., Torata, N., Moriyama, T., Miyasaka, Y., Ohtsuka, T., Takahata, S., Mizumoto, K., Oda, Y., Tanaka, M."TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells". International Journal of Oncology 47.2 (2015): 490-498.
Chicago
Zheng, B., Ohuchida, K., Cui, L., Zhao, M., Shindo, K., Fujiwara, K., Manabe, T., Torata, N., Moriyama, T., Miyasaka, Y., Ohtsuka, T., Takahata, S., Mizumoto, K., Oda, Y., Tanaka, M."TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells". International Journal of Oncology 47, no. 2 (2015): 490-498. https://doi.org/10.3892/ijo.2015.3022